Drug Profile
Dronedarone - Sanofi
Alternative Names: Drondarone; Dronedarone hydrochloride; Multag; Multaq; SB-33589; SR 33589; SR 33589BLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class Antiarrhythmics; Benzofurans; Class III antiarrhythmics; Ischaemic heart disorder therapies; Small molecules
- Mechanism of Action Calcium channel antagonists; Potassium channel antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Atrial fibrillation; Atrial flutter
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Atrial-fibrillation(Combination therapy, In volunteers) in France (PO, Tablet)
- 10 May 2017 Launched for Atrial fibrillation in Greece, Hungary, Australia and China (PO) before May 2017
- 11 Jul 2011 European Medicines Agency broadens ongoing benefit-risk assessment of dronedarone to include review of cardiovascular risk